To determine whether GR regulates immunity-related genes in pancreatic cancer cells, we treated two human PDAC cell lines harboring the G12D hotspot mutation of KRAS24,25, SU86.86 (female) and SW1990 (male), with the clinical GR antagonist mifepristone (also known as RU486; used to treat patients with Cushing’s syndrome characterized by aberrantly high levels of glucocorticoids)26–28. Here, NR3C1 is linked to familial pancreatic carcinoma.